Metastatic Clear Cell Renal Cell Carcinoma to Pancreas and Distant Organs 24 Years After Radical Nephrectomy: A Case Report and Literature Review

Overview

Journal Front Surg

Specialty General Surgery

Date 2022 Jul 22

PMID 35865042

Authors

Huawei Cao

Zejia Sun

Jiyue Wu

Changzhen Hao

Wei Wang

Affiliations

Soon will be listed here.

Abstract

Background: Clear cell renal cell carcinoma (CCRCC) is a common urological neoplasm, and even though surgical resection is effective for localized CCRCC, the prognosis of metastatic CCRCC is poor. Currently, there is a paucity of recognized effective therapeutic protocols for metastatic CCRCC.

Case Presentation: A 76-year-old Asian man underwent radical left nephrectomy for CCRCC 26 years ago; this patient visited our hospital with abdominal pain due to multiple abdominal metastases 24 years after the nephrectomy. After metastasectomy, he underwent targeted therapy combined with a programmed death receptor-1 (PD-1) inhibitor, and the current imaging results indicate remarkable tumor remission.

Conclusions: Metachronous pancreatic metastasis from CCRCC after nephrectomy is rare, but clinicians and patients should not ignore this possibility. The combination of targeted therapy and immunotherapy can result in satisfactory outcomes in cases where metastatic CCRCC continues to progress despite metastasectomy and targeted therapy. The combination of local and systemic therapy can be an effective therapeutic protocol for metastatic CCRCC, but there is no consensus on suitable therapeutics.

Citing Articles

Current Practice and Outcomes of Patients Undergoing Surgical Resection for Renal Cell Metastases to the Pancreas in Northern Ireland.

Dodds K, Curry D, Kelly P, ORourke D, McClements J Ulster Med J. 2024; 93(2):58-66.

PMID: 39669950 PMC: 11633314.

Comprehensive analysis reveals the involvement of hsa_circ_0037858/miR-5000- axis in malignant metastasis of clear cell renal cell carcinoma.

Nianyong Y, Li G Aging (Albany NY). 2023; 15(12):5399-5411.

PMID: 37379126 PMC: 10333075. DOI: 10.18632/aging.204790.

Metastatic Renal Cell Carcinoma to Pancreas: Case Series and Review of the Literature.

Balaban D, Coman L, Marin F, Balaban M, Tabacelia D, Vasilescu F Diagnostics (Basel). 2023; 13(8).

PMID: 37189469 PMC: 10137405. DOI: 10.3390/diagnostics13081368.

Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy.

Lou Y, Guo K, Zheng S Front Oncol. 2023; 13:1091635.

PMID: 36845747 PMC: 9948010. DOI: 10.3389/fonc.2023.1091635.

FBXO30 functions as a tumor suppressor and an E3 ubiquitin ligase for hZIP1‑mediated HIF‑1α degradation in renal cell carcinoma.

Yuan Y, Liu Z, Li B, Gong Z, Piao C, Liu Z Int J Oncol. 2023; 62(3).

PMID: 36799168 PMC: 9946804. DOI: 10.3892/ijo.2023.5488.

References

Zhang C, OShea A, Parente C, Amorim B, Caravan P, Ferrone C . Evaluation of the Diagnostic Performance of Positron Emission Tomography/Magnetic Resonance for the Diagnosis of Liver Metastases. Invest Radiol. 2021; 56(10):621-628. DOI: 10.1097/RLI.0000000000000782. View

Johns A, Wei L, Grogan M, Hoyd R, Bridges J, Patel S . Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. J Geriatr Oncol. 2021; 12(5):813-819. PMC: 8184608. DOI: 10.1016/j.jgo.2021.02.002. View

Bianchi M, Sun M, Jeldres C, Shariat S, Trinh Q, Briganti A . Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2011; 23(4):973-80. DOI: 10.1093/annonc/mdr362. View

Janzen N, Kim H, Figlin R, Belldegrun A . Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003; 30(4):843-52. DOI: 10.1016/s0094-0143(03)00056-9. View

Sperti C, Pozza G, Brazzale A, Buratin A, Moletta L, Beltrame V . Metastatic tumors to the pancreas: a systematic review and meta-analysis. Minerva Chir. 2016; 71(5):337-44. View

Hsiang W, Kenney P, Leapman M . Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. Curr Oncol Rep. 2020; 22(4):35. DOI: 10.1007/s11912-020-0895-y. View

Rupert K, Kural T, Skalicky T, Zeithaml J, Hess O, Treska V . Clear cell renal carcinoma metastases to the pancreas. Rozhl Chir. 2020; 99(7):311-315. DOI: 10.33699/PIS.2020.99.7.311-315. View

Alzahrani A, Aggamy M, Joudeh A, Alabdullatif H, Alzahrani H, Gomha M . Metastasectomy of Sequential Asynchronous Metastatic Renal Cell Carcinoma to the Pancreas, Thyroid, Skin, Contralateral Kidney, and Lung with Cumulative Survival Beyond 10 Years: A Case Report and Clinicopathologic Review. Am J Case Rep. 2021; 22:e931696. PMC: 8112462. DOI: 10.12659/AJCR.931696. View

Buttigliero C, Allis S, Tucci M, Zichi C, Leone G, Di Stefano R . Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. Cancer Treat Rev. 2018; 69:215-223. DOI: 10.1016/j.ctrv.2018.07.010. View

10.

Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M . Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2015; 27(2):366. DOI: 10.1093/annonc/mdv589. View

11.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

12.

Kroeze S, Fritz C, Schaule J, Siva S, Kahl K, Sundahl N . Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. BJU Int. 2020; 127(6):703-711. DOI: 10.1111/bju.15284. View

13.

Bhindi B, Abel E, Albiges L, Bensalah K, Boorjian S, Daneshmand S . Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol. 2018; 75(1):111-128. DOI: 10.1016/j.eururo.2018.09.016. View

14.

Cheung P, Patel S, North S, Sahgal A, Chu W, Soliman H . Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. Eur Urol. 2021; 80(6):693-700. DOI: 10.1016/j.eururo.2021.07.026. View

15.

Laru L, Ronkainen H, Ohtonen P, Vaarala M . Nephrectomy improves the survival of metastatic renal cell cancer patients with moderate to good performance status-results from a Finnish nation-wide population-based study from 2005 to 2010. World J Surg Oncol. 2021; 19(1):190. PMC: 8240260. DOI: 10.1186/s12957-021-02308-0. View

16.

Powles T, Atkins M, Escudier B, Motzer R, Rini B, Fong L . Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. Eur Urol. 2021; 79(5):665-673. PMC: 9357270. DOI: 10.1016/j.eururo.2021.01.003. View

17.

Hsieh P, Hung S, Li J, Wang S, Yang C, Chen C . The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis. Urol Oncol. 2021; 39(7):422-430. DOI: 10.1016/j.urolonc.2021.02.026. View

18.

Motzer R, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J . Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17(8):2530-40. DOI: 10.1200/JCO.1999.17.8.2530. View

19.

Ishihara H, Takagi T, Kondo T, Fukuda H, Tachibana H, Yoshida K . Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. Urol Oncol. 2020; 39(1):77.e17-77.e25. DOI: 10.1016/j.urolonc.2020.08.011. View

20.

Li J, Xue F, Xu X, Wang Q, Zhang X . Dynamic contrast-enhanced MRI differentiates hepatocellular carcinoma from hepatic metastasis of rectal cancer by extracting pharmacokinetic parameters and radiomic features. Exp Ther Med. 2020; 20(4):3643-3652. PMC: 7444351. DOI: 10.3892/etm.2020.9115. View